VanEck Associates
PACB icon

VanEck Associates’s Pacific Biosciences PACB Stock Holding History

VanEck Associates’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,916
Closed -$18K – 1407
2024
Q1 		$18K Buy
4,916
+506
+11% +$2.96K ﹤0.01% 1318
2023
Q4 		$43K Buy
4,410
+917
+26% +$7.5K ﹤0.01% 1293
2023
Q3 		$29K Buy
3,493
+374
+12% +$4.27K ﹤0.01% 1317
2023
Q2 		$41K Buy
3,119
+351
+13% +$4.27K ﹤0.01% 1311
2023
Q1 		$32K Buy
2,768
+303
+12% +$3.01K ﹤0.01% 1333
2022
Q4 		$20K Buy
2,465
+686
+39% +$5.91K ﹤0.01% 1360
2022
Q3 		$10K Buy
+1,779
New +$10.2K ﹤0.01% 1338

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates's PACB Position: Q2 2024 in Review

VanEck Associates sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 4,916 shares — an estimated $18K sold.

VanEck Associates first reported a position in PACB in Q3 2022 and held it in 7 quarters. The position peaked at $43K in Q4 2023. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • VanEck Associates reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • VanEck Associates sold 4,916 Pacific Biosciences shares in Q2 2024, an estimated $18K.
  • VanEck Associates first reported a position in Pacific Biosciences in Q3 2022 and held it in 7 quarters.
  • VanEck Associates's Pacific Biosciences position peaked at $43K in Q4 2023.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on VanEck Associates's 13F filing for Q2 2024, filed 31 Jul 2024.